Which medicines are affected by the reimbursement change?

The change affects almost all medicinal products in the group of angiotensin II antagonists as well as the medicinal product aliskiren. The table below is a list of the new reimbursement status for the medicinal products concerned in ATC group C09, listed here with the name of the active substances. The names of the medicinal products can be seen in the fact box to the right ('Current and future reimbursement for the medicines'). There are no changes to the reimbursement status of the ACE inhibitors.

The reimbursement status as at 15 November 2010 for the medicinal products for cardiovascular disease in ATC group C09 for which the reimbursement will be changed.

* Medicinal products containing losartan were granted general reimbursement on 19 April 2010 (see link in the fact box at the right).

The reimbursement status of all other cardiovascular products ('antihypertensives') which are not mentioned in the table will remain unchanged, and the vast majority of them will be granted general reimbursement.

General reimbursement means that reimbursement is automatically granted when the general practitioner prescribes the medicinal product.

No general reimbursement means that patients must pay the full amount themselves.

For further information, please contact Head of Department for Reimbursement Karen Kolenda on tel. +45 4488 9348.

Danish Medicines Agency, 14 June 2010 (last updated 25 October 2010)